Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.

Prestige Consumer Healthcare closed its largest deal on June 15, buying the Breathe Right brand and other OTC labels from Foundation Consumer Healthcare for $1.045B. The acquisition adds ~$200M in annual revenue and ~$95M EBITDA, and it expands Prestige’s positions in sleep, allergy/congestion, and oral pain relief, while management has positioned Dramamine/Fleet for GLP-1-related nausea/constipation. The key offset is leverage: net leverage is ~4.0x EBITDA at closing, with management targeting sub-3.0x by fiscal 2028, which depends on successful integration and free-cash-flow execution.

Analysis

PBH is less a growth story than a leverage-and-execution story. The acquisition increases reported scale, but the equity only works if management converts the acquired EBITDA into durable free cash flow fast enough to pull leverage down before refinancing risk starts to matter; at ~4x net leverage, every miss on working capital, integration cost, or promo intensity has an outsized effect on valuation.

The second-order winner is not just PBH’s top line but its shelf power: larger route-to-market economics can let it bundle slower brands into retailer resets and defend space against private label and larger OTC incumbents. That pressures nearby competitors with weaker brand equity in cough/cold, sleep, and oral care—especially those relying on undifferentiated formulations—because PBH can spend more efficiently on a broader brand platform rather than one SKU at a time.

The market may be underestimating how small the GLP-1 sidecar is relative to the balance-sheet risk. If the consumer thesis works, the rerating comes from de-levering and margin stability over 6-18 months, not from any near-term category inflection; if it fails, the downside shows up first in credit spreads and then in equity multiple compression. Falsifiers: leverage not trending below ~3.5x by the next two reporting cycles, incremental ad spend failing to lift sell-through, or a softer consumer forcing trade-down that offsets brand investment.

Key Decisions for Investors

• PBH: small starter long only on a 5-7% pullback, with a 6-18 month horizon; target a deleveraging rerate if management proves cash conversion and moves net leverage toward the low-3x area.
• PBH equity / PBH credit: avoid adding to the capital structure via bonds until post-close integration proves out; the equity is effectively a levered call on free cash flow, so a widening spread would be an early warning signal.
• Pair trade: long PBH / short a broader defensive consumer staple proxy or an OTC peer basket for 3-6 months if you want exposure to brand consolidation without paying full multiple for slower organic growth; cover if PBH misses post-merger synergy milestones.
• Set an alert for the next two earnings prints: if management does not show sequential deleveraging and stable gross margin despite acquisition-related investment, the stock likely deserves de-rating rather than patience.